Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MRT5413 in Adults
NCT05650554Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Molecular Glues
- Countries
- 3
01
Overview
A Phase 2 trial of quadrivalent influenza mrna vaccine mrt5413 in influenza, sponsored by Sanofi. Started Dec 2022; status: completed.
02
Drugs
quadrivalent influenza mrna vaccine mrt5413
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05650554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650554.